ACE I/D genotype-related increase in ACE plasma activity is a better predictor for schizophrenia diagnosis than the genotype alone

[1]  Y. Lee,et al.  The insertion/deletion polymorphism in the angiotensin-converting enzyme and susceptibility to schizophrenia or Parkinson’s disease: A meta-analysis , 2015, Journal of the renin-angiotensin-aldosterone system : JRAAS.

[2]  A. Gadelha,et al.  Factor structure of the Positive and Negative Syndrome Scale (PANSS) in Brazil: convergent validation of the Brazilian version. , 2014, Revista brasileira de psiquiatria.

[3]  S. D. de Souza,et al.  High-Throughput Sequencing of a South American Amerindian , 2013, PloS one.

[4]  A. Jaggi,et al.  Angiotensin as stress mediator: role of its receptor and interrelationships among other stress mediators and receptors. , 2013, Pharmacological research.

[5]  R. Kahn,et al.  Schizophrenia is a cognitive illness: time for a change in focus. , 2013, JAMA psychiatry.

[6]  J. Harding,et al.  A Role for the Brain RAS in Alzheimer’s and Parkinson’s Diseases , 2013, Front. Endocrinol..

[7]  G. Guyatt,et al.  Effects of centrally acting ACE inhibitors on the rate of cognitive decline in dementia , 2013, BMJ Open.

[8]  J. Sato,et al.  Plasma Ndel1 enzyme activity is reduced in patients with schizophrenia--a potential biomarker? , 2013, Journal of psychiatric research.

[9]  S. Ristić,et al.  Angiotensin-converting enzyme gene insertion/deletion polymorphism is not associated with schizophrenia in a Croatian population. , 2012, Psychiatric genetics.

[10]  Koji Yamada,et al.  Effect of a centrally active angiotensin converting enzyme inhibitor, perindopril, on cognitive performance in chronic cerebral hypo-perfusion rats , 2011, Brain Research.

[11]  John W. Wright,et al.  Brain renin-angiotensin—A new look at an old system , 2011, Progress in Neurobiology.

[12]  I. Degirmenci,et al.  Investigation of association between Angiotensin-converting enzyme gene insertion/deletion polymorphism frequency in Turkish patients with schizophrenia. , 2010, Genetic testing and molecular biomarkers.

[13]  A. Dupont,et al.  Brain angiotensin peptides regulate sympathetic tone and blood pressure , 2010, Journal of hypertension.

[14]  E. Ozkok,et al.  Angiotensin-converting enzyme polymorphism in schizophrenia, bipolar disorders, and their first-degree relatives , 2010, Psychiatric genetics.

[15]  E. Parellada,et al.  Insertion/deletion polymorphism of the angiotensin-converting enzyme gene is associated with schizophrenia in a Spanish population , 2009, Psychiatry Research.

[16]  S. Kubota,et al.  Protective effect of captopril and enalaprilat, angiotensin-converting enzyme inhibitors, on para-nonylphenol-induced *OH generation and dopamine efflux in rat striatum. , 2008, Toxicology.

[17]  P. Kehoe,et al.  Is inhibition of the renin–angiotensin system a new treatment option for Alzheimer's disease? , 2007, The Lancet Neurology.

[18]  L. Juliano,et al.  A continuous fluorescence resonance energy transfer angiotensin I-converting enzyme assay , 2006, Nature Protocols.

[19]  Norazrina Azmi,et al.  Effects of a neurotensin analogue (PD149163) and antagonist (SR142948A) on the scopolamine-induced deficits in a novel object discrimination task , 2006, Behavioural pharmacology.

[20]  N. Brandon,et al.  Inhibition of NUDEL (nuclear distribution element-like)-oligopeptidase activity by disrupted-in-schizophrenia 1. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[21]  D. Weinberger,et al.  Remission in schizophrenia: proposed criteria and rationale for consensus. , 2005, The American journal of psychiatry.

[22]  L. Abramova,et al.  [Insertion-deletion polymorphism of angiotensin-1-converting enzyme gene in patients with endogenic psychoses]. , 2005, Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova.

[23]  K. Niwa,et al.  Effects of brain-penetrating ACE inhibitors on Alzheimer disease progression , 2004, Neurology.

[24]  I. Modai,et al.  Angiotensin converting enzyme gene insertion/deletion polymorphism: case-control association studies in schizophrenia, major affective disorder, and tardive dyskinesia and a family-based association study in schizophrenia. , 2002, American journal of medical genetics.

[25]  N. Terragno,et al.  History about the discovery of the renin-angiotensin system. , 2001, Hypertension.

[26]  S. Tsai,et al.  Association Study of Angiotensin-Converting Enzyme Gene Polymorphism with Schizophrenia and Polydipsia , 2001, Neuropsychobiology.

[27]  J. Krieger,et al.  Standardization of a fluorimetric assay for the determination of tissue angiotensin-converting enzyme activity in rats. , 2000, Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas.

[28]  R. Rimón,et al.  Cerebrospinal fluid angiotensin-converting enzyme (ACE) correlates with length of illness in schizophrenia , 2000, Schizophrenia Research.

[29]  R. Rimón,et al.  Higher cerebrospinal fluid angiotensin-converting enzyme levels in neuroleptic-treated than in drug-free patients with schizophrenia. , 1998, Schizophrenia bulletin.

[30]  L. Liming,et al.  An insertion/deletion polymorphism in the angiotensin converting enzyme gene is associated with both brain substance P contents and affective disorders , 1996, Biological Psychiatry.

[31]  R. Rimón,et al.  Elevated angiotensin-converting enzyme (kininase II) in the cerebrospinal fluid of neuroleptic-treated schizophrenic patients , 1993, Schizophrenia Research.

[32]  G. Donnan,et al.  Angiotensin II receptor binding associated with nigrostriatal dopaminergic neurons in human basal ganglia , 1992, Annals of neurology.

[33]  P Corvol,et al.  An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. , 1990, The Journal of clinical investigation.

[34]  W. Gattaz,et al.  Low angiotensin-converting enzyme activity (kininase II) in cerebrospinal fluid of schizophrenics. , 1984, Biological psychiatry.

[35]  L. Iversen,et al.  Reduction of angiotensin-converting enzyme in substantia nigra in early-onset schizophrenia. , 1979, The New England journal of medicine.